| Literature DB >> 35612695 |
Ruijie Zhang1,2, Jiajia Meng1,2,3, Xiaojie Wang4, Liyuan Pu1,2, Tian Zhao1,2, Yi Huang5,6,7, Liyuan Han8,9.
Abstract
Ischemic stroke (IS) is the most prevalent type of stroke. The early diagnosis and prognosis of IS are crucial for successful therapy and early intervention. Metabolomics, a tool in systems biology based on several innovative technologies, can be used to identify disease biomarkers and unveil underlying pathophysiological processes. Accordingly, in recent years, an increasing number of studies have identified metabolites from cerebral ischemia patients and animal models that could improve the diagnosis of IS and prediction of its outcome. In this paper, metabolomic research is comprehensively reviewed with a focus on describing the metabolic changes and related pathways associated with IS. Most clinical studies use biofluids (e.g., blood or plasma) because their collection is minimally invasive and they are ideal for analyzing changes in metabolites in patients of IS. We review the application of animal models in metabolomic analyses aimed at investigating potential mechanisms of IS and developing novel therapeutic approaches. In addition, this review presents the strengths and limitations of current metabolomic studies on IS, providing a reference for future related studies.Entities:
Keywords: Biomarkers; Ischemic stroke; Metabolism; Metabolomics; Molecular diagnosis; Stroke
Mesh:
Substances:
Year: 2022 PMID: 35612695 DOI: 10.1007/s11011-022-01011-7
Source DB: PubMed Journal: Metab Brain Dis ISSN: 0885-7490 Impact factor: 3.655